Ionis Pharmaceuticals Inc
IONS
View Detailed Chart
86.500USD
+3.020+3.62%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
13.94BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.62%
5 Days
+4.63%
1 Month
+6.15%
6 Months
+112.58%
Year to Date
+9.34%
1 Year
+165.09%
View Detailed Chart
TradingKey Stock Score of Ionis Pharmaceuticals Inc
Currency: USD Updated: 2026-02-06Key Insights
Ionis Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 89.83.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ionis Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ionis Pharmaceuticals Inc Highlights
StrengthsRisks
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.14M.
Undervalued
The company’s latest PE is -53.80, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 176.98M shares, decreasing 4.54% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 2.04K shares of this stock.
Analyst Rating
Based on
23
analysts
Buy
Current Rating
89.830
Target Price
+7.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ionis Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ionis Pharmaceuticals Inc Info
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ticker SymbolIONS
CompanyIonis Pharmaceuticals Inc
CEOMonia (Brett P)
Websitehttps://www.ionis.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68204.600
-1765.530 (-2.52%)
282.580
+22.390 (+8.61%)
2015.510
-36.220 (-1.76%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
